Logo Logo
Hilfe
Hilfe
Switch Language to English

Weber, Sabine und Gerbes, Alexander L. (2022): Challenges and Future of Drug-Induced Liver Injury Research-Laboratory Tests. In: International Journal of Molecular Sciences, Bd. 23, Nr. 11, 6049

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Drug-induced liver injury (DILI) is a rare but potentially severe adverse drug event, which is also a major cause of study cessation and market withdrawal during drug development. Since no acknowledged diagnostic tests are available, DILI diagnosis poses a major challenge both in clinical practice as well as in pharmacovigilance. Differentiation from other liver diseases and the identification of the causative agent in the case of polymedication are the main issues that clinicians and drug developers face in this regard. Thus, efforts have been made to establish diagnostic testing methods and biomarkers in order to safely diagnose DILI and ensure a distinguishment from alternative liver pathologies. This review provides an overview of the diagnostic methods used in differential diagnosis, especially with regards to autoimmune hepatitis (AIH) and drug-induced autoimmune hepatitis (DI-AIH), in vitro causality methods using individual blood samples, biomarkers for diagnosis and severity prediction, as well as experimental predictive models utilized in pre-clinical settings during drug development regimes.

Dokument bearbeiten Dokument bearbeiten